168 related articles for article (PubMed ID: 23095132)
1. Effect of ethnicity on erythropoietin therapy response for hemodialysis patients: a retrospective study.
Al-Khalaf B; Al-Khalaf N; Mustafa S
Hemodial Int; 2013 Oct; 17(4):510-6. PubMed ID: 23095132
[TBL] [Abstract][Full Text] [Related]
2. [The use of erythropoietin beta, two to three times per week, once per week and once every other week: meta-analysis of two clinical trials].
Pljesa S
Med Pregl; 2007; 60(3-4):123-7. PubMed ID: 17853722
[TBL] [Abstract][Full Text] [Related]
3. Computerized decision support for EPO dosing in hemodialysis patients.
Miskulin DC; Weiner DE; Tighiouart H; Ladik V; Servilla K; Zager PG; Martin A; Johnson HK; Meyer KB;
Am J Kidney Dis; 2009 Dec; 54(6):1081-8. PubMed ID: 19781831
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study of the efficacy of different regimens of intermittent subcutaneous dosing of erythropoietin beta in treatment of renal anemia in chronic dialysis patients].
Nesić V; Ostrić V; Kovacević Z; Dimković N; Curić S; Lazarević M; Ratković M; Bogdanović J; Jelacić R
Med Pregl; 2005; 58(5-6):279-85. PubMed ID: 16526235
[TBL] [Abstract][Full Text] [Related]
5. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
6. [The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial].
Chen N; Qian JQ; Mei CL; Zhang AH; Xing CY; Wang L; Liu WH; Wang M; Chen JH; Liu BC; Hou FF; Chen XM; Zuo L; Shi W; Yu LB; Zhang Y
Zhonghua Nei Ke Za Zhi; 2012 Jul; 51(7):502-7. PubMed ID: 22943819
[TBL] [Abstract][Full Text] [Related]
7. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
[TBL] [Abstract][Full Text] [Related]
8. Dose conversion ratio in hemodialysis patients switched from darbepoetin alfa to PEG-epoetin beta: AFFIRM study.
Choi P; Farouk M; Manamley N; Addison J
Adv Ther; 2013 Nov; 30(11):1007-17. PubMed ID: 24173670
[TBL] [Abstract][Full Text] [Related]
9. Relationship between protein-energy wasting in adults with chronic hemodialysis and the response to treatment with erythropoietin.
González-Ortiz A; Correa-Rotter R; Vázquez-Rangel A; Vega-Vega O; Espinosa-Cuevas Á
BMC Nephrol; 2019 Aug; 20(1):316. PubMed ID: 31412807
[TBL] [Abstract][Full Text] [Related]
10. Intractable anemia among hemodialysis patients: a sign of suboptimal management or a marker of disease?
Kausz AT; Solid C; Pereira BJ; Collins AJ; St Peter W
Am J Kidney Dis; 2005 Jan; 45(1):136-47. PubMed ID: 15696453
[TBL] [Abstract][Full Text] [Related]
11. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study.
Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA;
BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687
[TBL] [Abstract][Full Text] [Related]
12. Iron-replete hemodialysis patients do not require higher EPO dosages when converting from subcutaneous to intravenous administration: results of the Italian Study on Erythropoietin Converting (ISEC).
Pizzarelli F; David S; Sala P; Icardi A; Casani A
Am J Kidney Dis; 2006 Jun; 47(6):1027-35. PubMed ID: 16731298
[TBL] [Abstract][Full Text] [Related]
13. Impact of nocturnal home hemodialysis on anemia management in patients with end-stage renal disease.
Schwartz DI; Pierratos A; Richardson RM; Fenton SS; Chan CT
Clin Nephrol; 2005 Mar; 63(3):202-8. PubMed ID: 15786821
[TBL] [Abstract][Full Text] [Related]
14. Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis.
Coronel F; Herrero JA; Montenegro J; Fernandez C; Gandara A; Conesa J; Rivera MT; Torrente J; Portolés J; Gomez-Martino JR
J Nephrol; 2003; 16(5):697-702. PubMed ID: 14733416
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of anemia with recombinant human erythropoietin and the bone marrow response in uremic patients undergoing periodic hemodialysis].
García Martín F; Carrascosa Vallejo T; Martín Escobar E; Val Begueria J; Martín Hernández R; de Arriba G; Teno C; Salvatierra J
Rev Clin Esp; 1990 May; 186(9):419-22. PubMed ID: 2247677
[TBL] [Abstract][Full Text] [Related]
16. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin: 18 months' experience in hemodialysis patients.
Canaud B; Polito-Bouloux C; Garred LJ; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
Am J Kidney Dis; 1990 Feb; 15(2):169-75. PubMed ID: 2301388
[TBL] [Abstract][Full Text] [Related]
18. Erythropoietin requirement in patients with type 2 diabetes mellitus on maintenance hemodialysis therapy.
Biesenbach G; Schmekal B; Eichbauer-Sturm G; Janko O
Wien Klin Wochenschr; 2004 Dec; 116(24):844-8. PubMed ID: 15690969
[TBL] [Abstract][Full Text] [Related]
19. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
[TBL] [Abstract][Full Text] [Related]
20. [Erythropoietin-beta in the treatment of anemia in patients with chronic renal insufficiency].
Dimković N
Med Pregl; 2001; 54(5-6):235-40. PubMed ID: 11759218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]